Has Ensifentrine been approved in China?

Ohtuvayre (Ensifentrine)-Ensifentrine Inhalation Suspension is an innovative drug that is developed as a dual-action drug that combines bronchodilator and anti-inflammatory effects for the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The mechanism of exefantine involves improving airway inflammation and airway resistance by inhibiting two key enzymes - cyclic adenosine monophosphate (cAMP) degrading enzyme and 5-phosphodiesterase. As a new type of drug, it shows good potential in treating chronic respiratory diseases.

However, regarding the marketing status of exefantine in China, the drug has not yet been approved by the China National Medical Products Administration (NMPA). Therefore, exefantine is not currently available in the domestic market, nor is it included in the medical insurance catalog. This means that domestic patients are temporarily unable to obtain the drug through formal channels, especially when it has not been included in the scope of medical insurance, and it is difficult for patients to enjoy cost compensation from medical insurance.

In the international market, exefantine has been approved in many countries and regions and is mainly used to treat chronic obstructive pulmonary disease (COPD) and asthma, especially in controlling symptoms and improving patients' quality of life. Despite this, the clinical use of exefantine has not been widely carried out in China, which is mainly restricted by factors such as the drug approval process, clinical trial data, and market policies.

As China gradually accelerates the approval process for new drugs, it is more likely that ensefentin will be approved in China in the future, especially in the treatment of chronic obstructive pulmonary disease and asthma. However, patients currently rely on other traditional medications to control symptoms.

In addition, with the changes in the global drug market, the drug may be available through international drug sales channels in the future, but it is necessary to carefully choose regular drug sources to avoid purchasing fake and shoddy drugs. Whether exefantine can be approved in the Chinese market still needs to wait for the support of more clinical data and market demand.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html